Pfizer moves early for Kissei's gout drug
This article was originally published in Scrip
Executive Summary
Pfizer has acquired exclusive global development and commercialization rights outside Japan to a drug for gout and hyperuricemia in early stage clinical development at the mid-sized Japanese firm Kissei Pharmaceutical.